Wassil Jim sold $127K of PCVX
Wassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares of Vaxcyte, Inc. (PCVX) at an average of $56.33 ($56.03–$57.82, $0.13M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; no other company developments are mentioned.
Market read
Traders may note the insider sale for sentiment monitoring, but it lacks fundamental follow-through in the text.
What to watch
The article provides no context on total insider ownership changes beyond post-sale holdings, nor any concurrent company news that could amplify the signal.
Background
This is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte COO Wassil Jim sold 2,250 shares in open-market trades totaling about $126.7K under a 10b5-1 plan.
Likely limited/short-lived impact; any move would be sentiment-driven rather than news-driven.
The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan and no accompanying operational, financial, or regulatory change described.
Market effects
Minimal—this is company-specific insider transaction data, not a sector-wide regulatory/clinical/financing event.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations; traders may discount it.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderWassil Jim
Chief Operating Officer who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan indicating the sale was scheduled rather than discretionary.
